Arcturus Therapeutics Holdings Inc (ARCT)

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like…

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024

By Chandler Capital, InvestorPlace Contributor Dec 13, 2023

These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 15, 2023

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Nov 14, 2023

Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

3 Biotech Stocks to Buy Before the Breakout

By Michael Que, InvestorPlace Contributor Jul 28, 2023

Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.

3 Biotech Stocks for Getting Rich in 2023

By Noah Bolton, InvestorPlace Contributor Jul 18, 2023

These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Mar 29, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?

By David Moadel, InvestorPlace Contributor Nov 2, 2022

The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 2, 2022

Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!

7 Small-Cap Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later

By Josh Enomoto, InvestorPlace Contributor Sep 22, 2022

With the market taking a dip and possibly poised to incur more red ink, these are the small-cap stocks to buy that appeal to contrarians.

7 Busted Biotech Stocks Due for a Rebound

By Chris Lau, InvestorPlace Contributor Sep 8, 2021

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally.

7 Best Vaccine Stocks for Their Pipeline Potential

By Faisal Humayun, InvestorPlace Contributor Jun 3, 2021

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer.

Be Careful with Novavax and the Recent Surge in NVAX Stock

By Luke Lango, InvestorPlace Senior Investment Analyst Jun 29, 2020

Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.

7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure

By Luke Lango, InvestorPlace Senior Investment Analyst May 28, 2020

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 “Perfect 10” Healthcare Stocks to Buy Now

By Maya Sasson, Writer, TipRanks Mar 18, 2020

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Evaluating NASDAQ:ARCT for Growth Investment Opportunities.

From Chartmill Feb 27, 2024

High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.

Arcturus gets EU orphan drug status for cystic fibrosis drug (NASDAQ:ARCT)

From Seeking Alpha Feb 22, 2024

Arcturus Therapeutics (ARCT) has received orphan drug designation from the European Commission for its drug candidate ARCT-032 in the treatment of cystic fibrosis. Read more here.

Is NASDAQ:ARCT suited for growth investing?

From Chartmill Feb 6, 2024

Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?

Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).

From Chartmill Jan 16, 2024

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations

From Chartmill Dec 26, 2023

Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).

Why the growth investor may take a look at NASDAQ:ARCT.

From Chartmill Dec 4, 2023

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

Arcturus Therapeutics Holdings Inc (ARCT)

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Arcturus Therapeutics Holdings Inc (ARCT)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ARCT Stock Predictions, Articles, and Arcturus Therapeutics Holdings Inc News

Subscriber Sign in